AstraZeneca’s BioVentureHub expanding with leading science
Two new companies have moved into the BioVentureHub at AstraZeneca Gothenburg, bringing the total to 17 companies and 1 academic group.
-
-
AstraZeneca PLC’s resultatrapport för helåret och fjärde kvartalet 2015
Pascal Soriot, koncernchef, kommenterar resultatet: "Vi stärkte vår forskningsportfölj och levererade ett starkt finansiellt resultat under 2015 samtidigt som vi påbörjade nästa fas av vår strategiska resa. .....
-
TAGRISSO™ (osimertinib) har godkänts i EU som den första behandlingen för patienter med EGFR T790M mutationspositiv metastaserad icke-småcellig lungcancer
Det första nya läkemedlet som godkänts inom ramen för Europeiska kommissionens accelererade process Godkännandet baseras på studier som visar på en objektiv responsfrekvens av 66 % och en progressionsfri överlevnad med en median på 9,7 månader. Tumörprov eller blodprov kan fastställa vilka patienter som sannolikt kan dra nytta av osimertinib
-
Tagrisso™ (osimertinib) approved in EU as first-in-class treatment for patients with EGFR T790m mutation-positive metastatic non-small cell lung cancer
TAGRISSO™ is the first new medicine to be approved under the European Commission’s expedited process
Approval based on studies showing objective response rate of 66% and median progression-free survival of 9.7 months
Tumour sample or blood test can determine patients likely to benefit from osimertinib
AstraZeneca today announced that the European Commission (EC) has granted condition -
Lynparza™ (olaparib) granted breakthrough therapy designation by US FDA for treatment of BRCA1/2 or ATM gene mutated metastatic Castration Resistant Prostate Cancer
AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for the oral poly ADP-ribose polymerase (PARP) inhibitor Lynparza™ (olaparib),
-
AstraZeneca and Incyte announce new lung cancer clinical trial collaboration
AstraZeneca and Incyte Corporation today announced a new collaboration to evaluate the efficacy and safety of Incyte’s Janus-associated kinase (JAK) 1 inhibitor, INCB39110, in combination with AstraZeneca’s next generation epidermal growth factor receptor (EGFR) inhibitor, Tagrisso® (osimertinib). The combination will be assessed as a second line treatment for patients with EGFR mutation-positive
-
AstraZeneca and Moderna Therapeutics announce new collaboration to co-develop and co-commercialise Immuno-Oncology mRNA Therapeutics™
Moderna to lead preclinical development; AstraZeneca to lead clinical development; Moderna to co-commercialise and share profits on resulting products in the US
AstraZeneca, along with its global biologics research and development arm, MedImmune, and Moderna Therapeutics today announced a new collaboration to discover, co-develop and co-commercialise messenger RNA (mRNA) therapeutic candidates -
ZURAMPIC® (lesinurad) approved by US FDA for patients with gout
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved ZURAMPIC®(lesinurad) 200mg tablets in combination with a xanthine oxidase inhibitor (XOI) for the treatment of hyperuricemia associated with gout
-
TAGRISSO™ (OSIMERTINIB) , LESINURAD OCH BRILIQUE (TICAGRELOR) FÅR POSITIVT UTLÅTANDE FRÅN CHMP I EU
AstraZeneca meddelar idag att den europeiska läkemedelsmyndigheten EMA:s rådgivande kommitté CHMP ger positivt besked och rekommenderar godkännande av TAGRISSO™ (AZD9291, osimertinib) och lesinurad, samt ny indikation för BRILIQUE (ticagrelor) 60mg för behandling av patienter som har en historia av hjärtinfarkt och hög risk att få en ytterligare aterotrombotisk händelse.
-
Durvalumab ATLANTIC trial supports clinical activity and AstraZeneca’s overall immuno-oncology strategy
Durvalumab demonstrated clinical activity and durable responses in 3rd-line or later stage NSCLC patients; full data to be presented at a scientific congress in 2016
-
AstraZeneca enhances long term growth through oncology investment in Acerta Pharma
Transaction includes late-stage, potential best-in-class irreversible small molecule BTK inhibitor, acalabrutinib Opportunity for first regulatory submissions in haematological malignancies in 2016
-
AstraZeneca continues strategic investment in China to accelerate delivery of innovative biologics and targeted medicines
Strategic alliance with WuXi AppTec to develop next-generation biologics in China New small molecule development facility; new global hub for Pharmaceutical Development
Visa mer
Loading...